This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Spironolactone and ACEI or ARBs - safety advice

Authoring team

Reminder for healthcare professionals:

  • concomitant use of spironolactone with ACEi or ARB is not routinely recommended because of the risks of severe hyperkalaemia, particularly in patients with marked renal impairment

  • use the lowest effective doses of spironolactone and ACEi or ARB if coadministration is considered essential

  • regularly monitor serum potassium levels and renal function

  • interrupt or discontinue treatment in the event of hyperkalaemia

Reference:

  • Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update February 2016.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page